Q4 2024 Management View CEO Herriot Tabuteau highlighted that Axsome has expanded its CNS portfolio to include three commercial products and three late-stage pipeline candidates. The company aims to ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Auvelity is approved for the treatment of adults with major depressive disorder (“MDD”). It is the first approved drug in Axsome’s portfolio. Auvelity was launched in the United States in 2022.

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Shares of Axsome Therapeutics ( AXSM -0.49%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...